PNOC has opened a new phase I trial of an oncolytic virus treatment for children and young adults with recurrent medulloblastoma or atypical teratoid/rhabdoid tumors (ATRT). This first-of-its-kind therapy is a new, targeted treatment option for patients who cannot be cured with standard care for these tumors.
The Pacific Pediatric Neuro-Oncology Consortium (PNOC) is a network of 15 children’s hospitals that conduct clinical trials of new therapies for children with brain tumors. Our goal is to improve outcomes by translating the latest findings in cancer biology into better treatments for these children.
Patients with brain tumors that cannot be treated with standard therapy, or that have recurred following standard therapy, are often eligible for clinical trials. Clinical trials provide access to promising new treatments that may not be available outside specialized centers.
At PNOC, our focus is personalized medicine – testing new therapies that are specific to the biology of each patient’s tumor to maximize their effectiveness. Our goal is to improve overall outcome for children with brain tumors.